pSivida signs new evaluation agreement for cardiovascular drug delivery

By Lisa Kerner

Erie, Pa., April 5 - pSivida Ltd. said it has entered into an agreement with an undisclosed large medical device company to evaluate cardiovascular delivery of drugs using pSivida's drug delivery technologies.

"This agreement demonstrates our drug delivery technology is being evaluated in areas beyond ophthalmology and oncology treatments," chief executive officer Gavin Rezos said in a company news release.

pSivida's Retisert and Vitrasert, licensed to Bausch & Lomb, are the only Food and Drug Administration-approved sustained release drug treatments to the back of the eye.

Both Retisert and Medidur release the same drug at the same rate into the eye. However, unlike Retisert, which is surgically implanted into the eye, Medidur is designed to be injected into the eye.

Medidur is licensed to Alimera Sciences for the treatment of diabetic macular edema and is currently in phase 3 clinical trials.

BrachySil is licensed to Beijing Med-Pharm as a new treatment for inoperable liver cancer. BrachySil is in phase 2b clinical trials in Singapore and is soon to be in phase 2a clinical trials for the treatment of inoperable pancreatic cancer.

pSivida is a global bio-nanotech company based in Boston.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.